MedTrace Logo

Safety and Efficacy Study of a New Treatment for Recurrent Symptoms of Oral Herpes Virus Infection

NCT01308424 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 171

Last updated 2013-08-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if a new treatment is effective for the treatment of recurrent symptomatic oral herpes virus infections.

Conditions

  • Oral Herpes Simplex

Interventions

DRUG

BTL TML HSV

Sublingual micro-dosing for 7 days

DRUG

Matching placebo

sublingual dosing for 7 days

Sponsors & Collaborators

  • Norwich Clinical Research Associates Ltd.

    collaborator OTHER

  • Beech Tree Labs, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2012-10-31
Completion
2012-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01308424 on ClinicalTrials.gov